Hemophilia A

Hemophilia A is an X-linked inherited bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII) due to pathogenic variants in the F8 gene, impairing the intrinsic tenase complex and leading to spontaneous and trauma-related bleeding ^[1]C4.

Also Called / Synonyms

• Hemophilia A (HA)
• Classic hemophilia (historical)
• Factor VIII deficiency
• Congenital factor VIII deficiency
• Abbreviations: HA, FVIII deficiency
• Carrier states (historical): Hemophilia carrier (HC), now replaced by ISTH nomenclature (see below) ^[6]A1c

Definition and Scope

The disease results from absent or dysfunctional FVIII, a critical cofactor in the intrinsic coagulation cascade that activates factor X. Without sufficient FVIII, clot formation is delayed and unstable, causing bleeding into joints (hemarthroses), soft tissues, and, less commonly, critical organs ^[1]C4. The condition manifests almost exclusively in males due to X-linked recessive inheritance, but symptomatic females are increasingly recognized ^[6]A1c[7]C4.

Classification Based on FVIII Activity

Hemophilia A severity is classified by baseline plasma FVIII activity level, which predicts bleeding phenotype and guides management :

Patients with FVIII activity ≥40% are generally asymptomatic and classified as normal ^[1]C4.

Revised ISTH Carrier Nomenclature

A 2021 ISTH Scientific and Standardization Committee (SSC) communication introduced a new nomenclature for women and girls with F8 variants, replacing the term "carrier" with five clinically distinct categories based on personal bleeding history and baseline FVIII level ^[6]A1c:

1. Asymptomatic hemophilia A
2. Symptomatic hemophilia A
3. Hemophilia A with mild severity
4. Hemophilia A with moderate severity
5. Hemophilia A with severe severity

This classification acknowledges that many females with F8 variants experience significant bleeding and require treatment, overcoming the historic bias that labeled all as asymptomatic carriers ^[6]A1c[7]C4.

Discrepant Hemophilia A (DHA)

A subset of patients, termed discrepant hemophilia A, exhibit a discrepancy between FVIII activity measured by one-stage clotting assay versus chromogenic assay, typically due to specific F8 missense mutations. Diagnosis is critical because one assay may show normal FVIII activity while the other shows low activity, leading to underdiagnosis or misclassification of severity ^[10]C4.

Revised Classification of FVIII Concentrates

A 2026 revision proposed novel metrics for classifying FVIII replacement products based on pharmacokinetic (PK) performance, beyond the traditional standard half-life (SHL) versus extended half-life (EHL) dichotomy:

• SHL-FVIII: Standard half-life (bound by von Willebrand factor [VWF] ceiling)
• EHL-FVIII: Extended half-life via Fc-fusion or PEGylation (∼30% increase in AUC vs SHL) ^[3]D5
• HSA/UL-FVIII: High-sustained-activity/ultralong half-life FVIII (eliminates VWF binding; achieves fourfold longer half-life and sixfold greater AUC vs SHL; maintains nonhemophilic FVIII activity for days after once-weekly dosing) ^[3]D5

This classification reflects advances in product engineering and PK modeling to optimize prophylaxis and bleeding prevention.

Clinical Significance

Hemophilia A affects approximately 1 in 5,000 to 10,000 males worldwide, making it one of the most common inherited bleeding disorders. Without modern prophylaxis, severe disease leads to progressive hemophilic arthropathy, disability, and reduced quality of life ^[1]C4[8]B2b. Early diagnosis and severity-appropriate management are essential to prevent joint destruction and life-threatening hemorrhages.

Pearl: Hemophilia A severity is dichotomized by baseline FVIII activity (<1%, 1-5%, >5-40%), guiding both bleeding risk and treatment intensity; however, globally up to 75% of individuals with hemophilia remain undiagnosed, particularly in resource-limited settings, underscoring the need for universal screening of at-risk families ^[1]C4.

The core defect is deficiency or dysfunction of coagulation factor VIII (FVIII) caused by heterogeneous mutations in the F8 gene, impairing the intrinsic tenase complex and fibrin clot generation. The F8 gene, located at Xq28, encodes a 2351‑amino acid glycoprotein with a domain structure of A1‑A2‑B‑A3‑C1‑C2. FVIII circulates bound to von Willebrand factor (VWF), which protects it from premature proteolysis and targets it to sites of vascular injury. Upon thrombin activation, FVIII is cleaved from VWF and acts as a cofactor for factor IXa (FIXa) on the phospholipid surface, accelerating factor X activation by 10⁵‑fold. Without functional FVIII, this amplification step is lost, and thrombin generation is severely reduced, predisposing to spontaneous and trauma‑related bleeding, especially into joints and soft tissues ^{[1]C4[11]A1b[18]D5}.

Molecular Basis of FVIII Deficiency

More than 2,100 unique F8 mutations have been catalogued, and the genotype-phenotype correlation is the primary determinant of clinical severity ^[18]D5. Intron 22 inversion (Inv22) accounts for 40-45% of severe hemophilia A, and intron 1 inversion (Inv1) for 3-5%; both disrupt the F8 gene by homologous recombination between intragenic and extragenic repeats, resulting in a completely non‑functional truncated protein ^{[23]D5[28]C4[29]C4}. Large deletions, nonsense mutations, and small insertions/deletions that cause frameshifts also produce null alleles with absent FVIII synthesis and a severe phenotype ^{[13]B2a[29]C4}. Missense mutations predominate in mild/moderate hemophilia and can exert pleiotropic effects: impaired protein folding, defective secretion, accelerated clearance, reduced specific activity, or altered splicing (e.g., the recurrent c.6046C>T/p.R2016W mutation reduces both correct splicing to 70% and secretion to 11% of wild‑type, compounding the defect) ^[31]D5[37]C4. Some missense mutations produce a cross‑reactive material‑positive (CRM+) phenotype with normal antigen levels but reduced function, as seen with the p.Lys1693Asn (FVIII‑Nara) mutation that resists thrombin cleavage at Arg1689 because of a P4′ substitution, leaving FVIII in an inactive state ^[35]D5.

Genetic Susceptibility and Inhibitor Development

Neutralizing anti‑FVIII antibodies (inhibitors) develop in 25-35% of patients with severe hemophilia A and represent the most serious treatment‑related complication. The risk is strongly linked to the underlying F8 mutation type ^[13]B2a. Null mutations (large deletions, nonsense, Inv22) confer the highest risk, with odds ratios exceeding 3‑fold compared with intron 22 inversion (reference) ^[13]B2a. In the SIPPET trial, null‑mutation patients had a cumulative inhibitor incidence of 31% when treated with plasma‑derived FVIII, whereas those with non‑null mutations had zero inhibitors ^[11]A1b. Nonsense mutations show wider variation in inhibitor risk, possibly because of translational readthrough at premature termination codons (PTCs): if readthrough yields trace amounts of near‑wild‑type FVIII, it may promote tolerance and lower inhibitor risk, whereas PTCs that preclude any full‑length FVIII production retain high immunogenicity ^[40]B2b.

Additional genetic modifiers include polymorphisms in the TNFA gene (‑308G>A variant) and the MHC class II region, which increase inhibitor risk by enhancing T‑helper cell activation ^{[12]B3b[17]B3b}. African American patients have a higher inhibitor incidence, partly due to unique F8 ns‑SNPs (e.g., FVIII‑H484, ‑E1241, ‑V2238) that generate peptides with increased binding to common HLA‑DRB1 molecules, triggering an immune response to the therapeutic FVIII ^[17]B3b.

Cellular Pathogenesis of Bleeding and Arthropathy

Recurrent joint bleeding (hemarthrosis) is the hallmark of severe hemophilia. The synovium is highly vascular and lacks tissue factor, making it dependent on the intrinsic pathway for hemostasis. Extravasated blood triggers an inflammatory cascade: iron from lysed erythrocytes drives synovial proliferation, neovascularization, and infiltration of CX3CR1+ macrophages ^[42]D5. The IL‑33/ST2 pathway amplifies this inflammatory response, promoting synovitis and catabolism of cartilage and bone ^[19]D5. Over time, this cycle leads to hemophilic arthropathy, a crippling combination of synovial hypertrophy, cartilage loss, and subchondral cyst formation. The inflammatory milieu also provides danger signals that may adjuvant the immune response to FVIII, further linking the bleeding phenotype to inhibitor risk ^[26]D5.

Acquired Hemophilia A

In contrast to the congenital disorder, acquired hemophilia A (AHA) is caused by autoantibodies (usually IgG4) that neutralize FVIII function. These inhibitors arise spontaneously in a previously normal hemostatic system, most often in older adults, and are associated with an underlying condition (malignancy, autoimmune disease, pregnancy) or drug exposure such as immune checkpoint inhibitors (anti‑PD‑1) ^[20]D5[38]C4. The antibodies block FVIII binding to phospholipids, FIXa, or VWF, leading to a severe bleeding diathesis (often with ecchymoses, muscle hematomas) that paradoxically does not involve joint bleeds as frequently as congenital hemophilia ^[20]D5. Inhibitor eradication requires immunosuppression, and the hemostatic defect can be bypassed with emicizumab or activated prothrombin complex concentrate ^[20]D5.

Special Mechanisms: Mild Hemophilia and Inhibitors

In mild/moderate hemophilia A, the risk of inhibitor development is much lower, but certain missense mutations (e.g., p.Pro1809Leu in the A3 domain) are associated with inhibitor formation. In these cases, the antibody may selectively inhibit allogeneic but not autologous FVIII, as the patient’s own FVIII carries the mutation that alters the epitope targeted by the antibody ^[21]C4. This phenomenon highlights the complexity of the immune response and the role of structural differences between endogenous and therapeutic FVIII.

Pearl: The clinical severity of hemophilia A is directly proportional to the residual FVIII activity, which is determined by the F8 mutation type; null mutations cause severe disease and carry the highest risk of inhibitor development, while missense mutations often yield milder phenotypes but may still trigger inhibitors through differential immune recognition of the mutant versus wild‑type FVIII ^{[13]B2a[21]C4[40]B2b}.

The global incidence of hemophilia A is remarkably consistent across populations: approximately 1 in 5,000 to 1 in 10,000 male births, corresponding to an incidence of 1-2 per 100,000 ^{[43]B2b[74]A1a}. Prevalence is estimated at 11 to 15 per 100,000 males, though this figure likely underestimates the true burden in regions without comprehensive registry data ^[74]A1a. A systematic review of African studies reported a pooled prevalence of 5.2 per 100,000 males (95% CI 3.3-7.2), with wide heterogeneity driven by differences in diagnostic capacity and healthcare access rather than true genetic variation ^[74]A1a. The disease affects all racial and ethnic groups, but the distribution of disease severity follows a predictable pattern from the underlying F8 mutation type (see Section 1).

Temporal Trends

The cumulative incidence of neutralizing anti-FVIII antibodies (inhibitors) has remained relatively stable over the past three decades, despite shifts in product type and treatment intensity. In previously untreated patients (PUPs) with severe hemophilia A, the pooled inhibitor incidence is approximately 30% (95% CI 27-33%) ^{[56]A1a[60]B2b}; approximately half of these are high-titer (>5 Bethesda Units) ^{[44]A1b[47]B2b}. The SIPPET trial demonstrated a higher rate with recombinant factor VIII (rFVIII) compared with plasma-derived FVIII containing von Willebrand factor (pdFVIII/VWF): 87% vs 65% cumulative inhibitor incidence at 50 exposure days (hazard ratio 1.87, 95% CI 1.17-2.96), with a NNT of approximately 6 to prevent one inhibitor by choosing pdFVIII/VWF over rFVIII ^[44]A1b. In previously treated patients (PTPs), the incidence is far lower, 2.06 per 1,000 person-years (95% CI 1.06-4.01), yet still clinically significant ^[55]A1a.

Risk Factors for Inhibitor Development

Inhibitor development is a multi-factorial process driven by genetic, product-related, and environmental factors. The most important are summarized in the table below.

Intracranial Hemorrhage: A Special Case

Intracranial hemorrhage (ICH) is the most feared early bleeding complication. The incidence in children with hemophilia is 2.2% (10 per 1,000 person-years) before age 3, with 75% of cases occurring before 1 year of age ^[67]B2b. Prophylaxis reduces ICH risk substantially, supporting the rationale for early initiation ^[67]B2b.

Seasonal and Geographic Variation

No robust seasonal variation in hemophilia A incidence or inhibitor development has been demonstrated. Geographic variation exists primarily in diagnosis rates. For example, a meta-analysis in Africa found prevalence estimates ranging from 0.2 to 18.5 per 100,000 males, driven largely by underdiagnosis rather than true differences in mutation frequency ^[74]A1a.

Pearl: Inhibitor risk is highest in PUPs with null F8 mutations, especially if treated with recombinant factor VIII; choosing pdFVIII/VWF for this high-risk subgroup reduces inhibitor incidence from approximately 87% to 65% (HR 1.87), with an estimated NNT of 6 ^[44]A1b.

The clinical phenotype of hemophilia A is a direct reflection of the residual factor VIII activity level, with bleeding severity inversely proportional to the circulating FVIII concentration. In severe disease (FVIII <1% of normal), spontaneous bleeding begins in infancy or early childhood, often heralded by easy bruising, hemarthrosis, or intracranial hemorrhage after birth ^[88]D5. Moderate deficiency (FVIII 1-5%) typically presents with occasional spontaneous bleeds and excessive bleeding after minor trauma, while mild disease (FVIII 5-40%) may remain silent until provoked by surgery, dental extraction, or significant injury ^[81]D5.

Hemarthrosis and Hemophilic Arthropathy

Recurrent joint bleeding is the hallmark of severe hemophilia A and the primary driver of long-term morbidity. The first hemarthrosis often occurs when a child begins to walk, most commonly in the ankles and knees, followed by the elbows ^[88]D5. Acute hemarthrosis presents with a warm, swollen, tender joint with limited range of motion; pain may be less prominent in young children. Repeated bleeding triggers a vicious cycle of synovial inflammation, cartilage degradation, and subchondral bone loss mediated by the iRhom2/ADAM17/TNF-α pathway ^[78]D5[85]D5. Over time, this progresses to hemophilic arthropathy, a disabling condition characterized by joint deformity, muscle atrophy, flexion contractures, and chronic pain ^[88]D5. Early prophylaxis with factor VIII replacement significantly reduces the incidence of joint bleeds and preserves joint structure, as demonstrated in the ESPRIT study ^[52]A1b and the Joint Outcome Continuation Study ^[76]B2b.

Muscle and Soft Tissue Bleeding

Intramuscular hematomas are the second most common bleeding manifestation. Iliopsoas hemorrhage presents with groin or hip pain, a flexed hip posture, and femoral nerve compression causing anterior thigh numbness and weakness. Bleeding into the forearm or calf can produce compartment syndrome, threatening neurovascular function. Retropharyngeal or retroperitoneal bleeds are less common but life-threatening.

Mucocutaneous and Other Bleeding

Epistaxis, oral mucosal bleeding, hematuria, and gastrointestinal bleeding occur but are less frequent than joint and muscle bleeds. Intracranial hemorrhage, though rare, is a catastrophic emergency that can occur spontaneously in severe disease or after minor head trauma. Petechiae are not a feature of hemophilia A and should prompt evaluation for platelet disorders or vasculitis ^[92]C4.

Bleeding in Carriers

Female carriers of hemophilia A are not merely silent transmitters; due to skewed X-inactivation, many have factor VIII levels in the mild-to-moderate range and experience clinically significant bleeding ^[80]C4[90]D5. Menorrhagia, postpartum hemorrhage , and excessive bleeding after dental or surgical procedures are common. Recognition of bleeding symptoms in carriers is essential for appropriate counseling and management ^[90]D5.

Acquired Hemophilia A

Acquired hemophilia A (AHA) is a distinct autoimmune disorder caused by autoantibodies against factor VIII, typically presenting in older adults with no prior bleeding history ^{[75]A1c[98]C4}. Patients develop spontaneous ecchymoses, intramuscular hematomas, and hematuria; hemarthrosis is less common than in congenital hemophilia. An isolated prolonged activated partial thromboplastin time (aPTT) in a patient with new-onset bleeding should raise suspicion for AHA ^[96]C4. AHA has been reported in association with autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis), malignancy, pregnancy, and rarely after vaccination ^{[83]C4[95]C4[97]C4[98]C4}.

Red Flags

• Intracranial hemorrhage: Any head trauma or sudden severe headache in a patient with hemophilia requires immediate evaluation.
• Compartment syndrome: Tense, painful muscle swelling with pallor, paresthesias, or pulselessness.
• Airway compromise: Neck swelling or dysphagia from retropharyngeal bleeding.

Pearl: The pattern of joint bleeding in severe hemophilia A is predictable, ankles and knees first, then elbows, and early prophylaxis with factor VIII replacement prevents the irreversible joint damage of hemophilic arthropathy ^{[52]A1b[76]B2b}.

The diagnostic pathway for hemophilia A begins with a clinical suspicion triggered by bleeding phenotype and family history, but the diagnosis is established by laboratory demonstration of reduced factor VIII (FVIII) activity. The single gold-standard diagnostic test is the one-stage clotting assay for FVIII activity (FVIII:C) ^[124]D5. A normal FVIII:C essentially excludes hemophilia A, while a low level confirms the diagnosis and defines severity (severe: <1 IU/dL; moderate: 1-5 IU/dL; mild: >5 to <40 IU/dL).

History and Physical

A focused bleeding history should probe for spontaneous hemarthroses (especially ankles, knees, elbows), easy bruising, prolonged bleeding after dental extraction or surgery, and intracranial hemorrhage (ICH) in infants ^[67]B2b. The physical examination may reveal joint swelling, warmth, and limited range of motion in acute hemarthrosis; chronic arthropathy shows fixed deformities and muscle atrophy. In neonates, ICH presents with lethargy, seizures, or bulging fontanelles ^[111]B2b. A three-generation family history is essential, noting X-linked inheritance pattern and any known female carriers ^[6]A1c.

Gold-Standard Test: Factor VIII Activity Assay

The one-stage clotting assay (based on activated partial thromboplastin time [aPTT]) is the most widely used and validated method for measuring FVIII:C ^[124]D5. It is sensitive to FVIII levels down to <1 IU/dL and correlates well with bleeding phenotype. However, approximately 30% of patients with mild hemophilia A show a discrepancy between one-stage and chromogenic assays, with the one-stage assay giving higher values ^[70]C4. In such cases, the chromogenic assay (which uses a synthetic substrate) is the confirmatory test and better reflects the true bleeding risk ^[70]C4. For severe hemophilia A, both assays agree. The Nijmegen-modified Bethesda assay is the gold standard for detecting and quantifying FVIII inhibitors (neutralizing antibodies) ^[118]A1c.

Laboratory Studies

The initial laboratory step is a prolonged aPTT with normal PT and TT. A mixing study (1:1 with normal plasma) that corrects immediately suggests factor deficiency; failure to correct after 2-hour incubation indicates an inhibitor (acquired hemophilia A or lupus anticoagulant) ^[96]C4. If the mixing study corrects, specific factor assays are performed. FVIII:C <40 IU/dL with normal VWF levels confirms hemophilia A. If VWF is low, consider von Willebrand disease type 2N, which also causes low FVIII:C due to defective VWF binding ^[33]D5.

Imaging

Imaging is not diagnostic for hemophilia A itself but is crucial for assessing joint health and bleeding complications. Ultrasound is the first-line modality for acute hemarthrosis, showing joint effusion and synovial hypertrophy. MRI is the gold standard for detecting early arthropathy (osteochondral changes, synovitis) and for monitoring progression ^[88]D5. In infants with suspected ICH, cranial ultrasound or CT is used emergently ^[67]B2b.

Biopsy / Histology

Biopsy is not required for the diagnosis of hemophilia A. However, in acquired hemophilia A (AHA), a tissue biopsy may be needed to exclude underlying malignancy or autoimmune disease ^[75]A1c. In congenital hemophilia, liver biopsy is occasionally performed in the context of gene therapy to assess vector-related inflammation ^[117]C4.

Diagnostic Algorithm

Step 1: Clinical suspicion (bleeding history, family history, isolated prolonged aPTT). Step 2: Perform aPTT, PT, TT, and mixing study.

• If mixing study corrects → proceed to FVIII:C assay.
• If mixing study does not correct → perform Bethesda assay for inhibitor. Step 3: Measure FVIII:C (one-stage). If <40 IU/dL and VWF normal → hemophilia A confirmed. Step 4: If mild hemophilia A (FVIII:C 5-40 IU/dL) and discrepancy suspected, perform chromogenic FVIII:C assay ^[70]C4. Step 5: If inhibitor suspected (acquired hemophilia A or congenital with inhibitor), perform Nijmegen Bethesda assay ^[118]A1c. Step 6: Offer genetic counseling and F8 gene sequencing for confirmation, carrier testing, and prenatal diagnosis ^{[18]D5[126]B2a}. Step 7: In female patients with low FVIII:C, assess for skewed X-inactivation, Turner syndrome mosaicism, or VWD type 2N ^{[6]A1c[33]D5[129]C4}.

First-Line Treatment at Diagnosis

Once the diagnosis is established, immediate management depends on severity and bleeding status:

• Mild hemophilia A (FVIII:C >5 IU/dL): Desmopressin (DDAVP) 0.3 µg/kg IV or intranasal (if known response) raises FVIII levels 2-4 fold; test dose recommended ^[124]D5.
• Moderate to severe hemophilia A (FVIII:C ≤5 IU/dL) with active bleeding: FVIII concentrate (recombinant or plasma-derived) at 50 IU/kg for major bleeds, 25 IU/kg for minor bleeds ^[124]D5.
• Severe hemophilia A without bleeding: Initiate prophylaxis with FVIII concentrate 25-40 IU/kg 3 times weekly or emicizumab (if inhibitor present) ^[124]D5.

Pearl: The one-stage FVIII assay is the initial gold standard, but a chromogenic assay is essential in mild hemophilia A to avoid misclassifying patients with discrepant results who have a higher bleeding risk than the one-stage assay suggests ^[70]C4.

Prognosis in hemophilia A is determined by a combination of genetic, clinical, and treatment-related factors, with validated scoring systems guiding risk stratification for inhibitor development, bleeding phenotype, and long-term outcomes. The most powerful predictor of disease trajectory is the underlying F8 mutation, which dictates both baseline factor activity and the risk of inhibitor formation ^[18]D5.

Genetic Risk Stratification for Inhibitor Development

The SIPPET trial demonstrated that previously untreated patients with severe hemophilia A carrying null mutations (large deletions, nonsense, frameshift) have a cumulative inhibitor incidence of 31% when treated with plasma-derived FVIII, compared to 0% in those with non-null mutations (missense, splice-site) ^[11]A1b. However, this protective effect of non-null mutations is lost when recombinant FVIII is used, emphasizing the interplay between genetic risk and product choice ^[11]A1b. Machine-learning models, such as the HemfilNET network, integrate clinical variables and pre-treatment biomarkers to predict inhibitor development with improved accuracy, identifying high-risk patients before the first exposure ^[141]B2b. These tools are increasingly incorporated into shared decision-making for product selection and prophylaxis intensity.

Clinical Severity Scores

The Hemophilia Severity Score (HSS) combines annual joint bleed rate, World Federation of Hemophilia orthopedic joint score, and annual factor consumption (adjusted for age at prophylaxis start and body weight) into a composite measure that correlates with clinical phenotype ^[140]C4. The Colorado Adult Joint Assessment Scale (CAJAS) provides a validated, joint-specific assessment of swelling, range of motion, contracture, and gait, with higher scores indicating worse arthropathy ^[134]B2b. Patient-reported outcomes, captured by the PROMIS Profile-29, offer complementary data on physical function, pain, fatigue, and social participation, and have been validated in adults with hemophilia ^[139]C4.

Prognosis in Acquired Hemophilia A

Acquired hemophilia A (AHA) carries a distinct prognostic profile. Baseline FVIII activity <1 IU/dL and the presence of anti-FVIII IgA autoantibodies are independent predictors of delayed remission and poor outcome ^{[131]B2b[136]B2b}. In the GTH-AH 01/2010 study, patients with FVIII <1 IU/dL achieved partial remission later (median 43 vs. 31 days) and less often (77% vs. 83%) than those with higher baseline levels ^[136]B2b. First-line immunosuppressive therapy with steroids alone yields success in 35.2%, while combination with cyclophosphamide improves success to 80.0% ^[142]B3b. Infection remains the leading cause of death, with overall mortality in AHA ranging from 10% to 20% in contemporary cohorts ^{[136]B2b[142]B3b}.

Long-Term Outcomes and Sequelae

Despite modern prophylaxis, many patients develop hemophilic arthropathy, chronic pain, and reduced quality of life. Joint bleeds, even when subclinical, lead to progressive cartilage damage and synovitis. Cardiovascular risk is an emerging concern in aging adults with hemophilia; the QRISK3 and Suita score have been validated in the ADVANCE Japan cohort to estimate 5-year arterial thrombotic risk, with observed event rates closely matching predictions ^[62]B2b. Population pharmacokinetic models enable individualized dosing to maintain FVIII trough levels above target thresholds, reducing breakthrough bleeds and joint deterioration ^[137]D5.

Recurrence Risk

Inhibitor recurrence after successful immune tolerance induction (ITI) occurs in a minority of patients. In a prospective study of low-dose ITI combined with rituximab , successful inhibitor eradication was achieved in the majority, but failure was associated with specific gene expression profiles, including upregulation of immune activation pathways ^[133]B2b. Long-term follow-up is essential, as late relapses can occur, particularly after intensive factor exposure or surgery.

Pearl: Genetic risk stratification using F8 mutation type is the cornerstone of inhibitor prediction, and validated composite scores (HSS, CAJAS, PROMIS-29) should be used routinely to monitor joint health and guide treatment intensity in both congenital and acquired hemophilia A ^{[11]A1b[140]C4[134]B2b}.

Step 1: Initial Assessment and Severity Classification

Immediately determine inhibitor status (known or suspected) and classify bleed severity. Life-threatening bleeds include intracranial hemorrhage (ICH), airway compromise, retroperitoneal bleeding, gastrointestinal hemorrhage, and large muscle bleeds with compartment syndrome. Non-life-threatening bleeds include hemarthroses and superficial soft-tissue hematomas. For any acute bleed, obtain a complete blood count , aPTT, factor VIII activity, and inhibitor titer if not already known ^[148]D5.

Step 2: First-Line Intervention

For patients without inhibitors: Administer factor VIII concentrate 50 IU/kg IV for major bleeds, followed by 25 IU/kg every 8-12 hours until hemostasis is achieved ^[148]D5. For life-threatening bleeds, give an initial bolus of 50-100 IU/kg, then maintain factor VIII levels >80% for the first 7 days via continuous infusion or intermittent dosing ^[148]D5.

For patients with inhibitors: Use a bypassing agent. Recombinant activated factor VII (rFVIIa) 90 mcg/kg IV every 2-3 hours is first-line ^[143]D5 (5). Alternatively, activated prothrombin complex concentrate (aPCC) 50-100 U/kg IV every 12 hours (maximum 200 U/kg/day) ^[143]D5 (5). Do not administer aPCC and rFVIIa concurrently due to additive thrombosis risk ^[143]D5. In patients on emicizumab prophylaxis, rFVIIa is preferred because aPCC co-administration increases thrombotic risk ^[144]C4 (4).

Figure 1: Acute bleed management algorithm (adapted from ^{[143]D5[148]D5}).

Step 3: Second-Line and Escalation

If bleeding persists despite one bypassing agent, switch to the other bypassing agent (e.g., from rFVIIa to aPCC or vice versa) ^[143]D5 (5). For life-threatening bleeds with low inhibitor titers (<5 Bethesda Units), high-dose FVIII concentrate (100-200 IU/kg) may overcome the inhibitor ^[143]D5. In refractory cases, consider plasmapheresis to reduce inhibitor titer, followed by FVIII infusion ^[143]D5. Imlifidase, an IgG-degrading enzyme, has been used experimentally to eliminate anti-FVIII antibodies and restore FVIII efficacy in inhibitor patients on emicizumab ^[144]C4 (4).

Step 4: Monitoring and Titration

Monitor clinical response: pain reduction, swelling, and range of motion for joint bleeds; vital signs and imaging for life-threatening bleeds. For ICH, maintain factor VIII levels >80-100% for 7-14 days with neurosurgical consultation ^[148]D5. For GI bleeds, maintain levels >50-80% and perform endoscopy ^[148]D5. For muscle bleeds with compartment syndrome, urgent fasciotomy may be required after factor replacement ^[148]D5.

Step 5: Resolution and Transition

Once hemostasis is achieved, taper factor replacement over 3-5 days for major bleeds. Transition to prophylaxis if not already on it (see Section 8). For inhibitor patients, initiate immune tolerance induction (ITI) after the acute bleed resolves ^[143]D5 (5).

Drug Comparison Table

Dosing Table

What NOT to Do

• Do not use desmopressin (DDAVP) for severe bleeds in severe hemophilia A; it is only effective in mild/moderate disease ^[148]D5.
• Do not administer NSAIDs or aspirin due to antiplatelet effects ^[148]D5.
• Do not give intramuscular injections during acute bleeding ^[148]D5.
• Do not combine aPCC and rFVIIa due to thrombosis risk ^[143]D5.

Controversies and Guideline Disagreement

Pearl: For acute bleeds in hemophilia A, immediate factor replacement is critical; in inhibitor patients, bypassing agents (rFVIIa or aPCC) are first-line, and rFVIIa is preferred in those on emicizumab due to thrombosis risk with aPCC ^{[143]D5[144]C4}.

Prophylaxis reduces annualized bleeding rates (ABR) by 80-90% compared with on-demand therapy, but the therapeutic landscape now offers multiple mechanistically distinct options that require individualized selection ^[169]A1c. The ISTH 2024 clinical practice guideline (GRADE-based) recommends prophylaxis over on-demand treatment for all patients with severe hemophilia A (strong recommendation, moderate-quality evidence) ^[169]A1c. The choice among factor VIII (FVIII) concentrates, non-factor therapies, and gene therapy depends on bleeding phenotype, inhibitor status, joint health, adherence, and patient preference.

Step 1: Selecting a Prophylaxis Regimen

Classify severity by baseline FVIII activity (<1% severe, 1-5% moderate, >5% mild) and assess bleeding phenotype (annual bleed rate, target joints, history of life-threatening hemorrhage). For patients with severe hemophilia A without inhibitors, first-line prophylaxis is either FVIII replacement therapy or a non-factor agent such as emicizumab ^[169]A1c. The ISTH guideline suggests emicizumab as an alternative to FVIII prophylaxis for patients without inhibitors (conditional recommendation, moderate-quality evidence) ^[169]A1c. For patients with inhibitors, emicizumab is recommended as first-line prophylaxis (strong recommendation, high-quality evidence) ^[169]A1c.

Step 2: Factor VIII Replacement Therapy

Standard half-life (SHL) FVIII concentrates require dosing every 2-3 days or three times weekly. Extended half-life (EHL) products, such as efanesoctocog alfa (Altuviiio), allow once-weekly dosing while maintaining FVIII activity above 40% for most of the week ^{[165]B2b[189]D5}. In the phase 3 XTEND-1 trial, once-weekly efanesoctocog alfa 50 IU/kg resulted in a mean ABR of 0.7 (95% CI 0.5-1.0) in adults, with 86% of patients experiencing zero treated bleeds ^[165]B2b. The median FVIII activity one week after dosing was 15 IU/dL (interquartile range 10-21) ^[165]B2b. In children <12 years, once-weekly efanesoctocog alfa 50 IU/kg produced a median ABR of 0.0 (95% CI 0.0-0.0) and a mean ABR of 0.5 ^[166]C4. No inhibitors were detected in either study ^{[165]B2b[166]C4}.

Step 3: Non-Factor Therapies

Non-factor agents provide subcutaneous prophylaxis with fixed dosing, eliminating the need for intravenous access.

Emicizumab (Hemlibra) is a bispecific monoclonal antibody that bridges activated factor IX and factor X, mimicking FVIIIa cofactor function. In the pooled HAVEN 1-4 analysis (N=401), the model-based treated ABR was 1.4 (95% CI 1.1-1.8) across a median efficacy period of 120.4 weeks ^[151]B2b. In HAVEN 1 (inhibitor patients), emicizumab prophylaxis reduced ABR by 87% compared with no prophylaxis (2.9 vs 23.3 events; rate ratio 0.13, 95% CI 0.07-0.24) ^[154]A1b. In HAVEN 3 (non-inhibitor patients), weekly emicizumab reduced ABR by 96% vs no prophylaxis (1.5 vs 38.2 events; rate ratio 0.04, 95% CI 0.02-0.08) ^[156]A1b. Emicizumab is approved for all ages, including infants <12 months (HAVEN 7) ^[161]C4.

Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody for once-daily subcutaneous use. In the explorer7 trial (inhibitor patients), concizumab prophylaxis reduced ABR by 86% vs no prophylaxis (median ABR 1.7 vs 11.8; rate ratio 0.14, 95% CI 0.07-0.28) ^[155]A1b. Longer-term data at 56 weeks confirmed sustained efficacy ^[162]A1b. In explorer8 (non-inhibitor patients), concizumab reduced ABR by 92% vs on-demand treatment (median ABR 0.0 vs 11.2; rate ratio 0.08, 95% CI 0.03-0.20) ^[204]A1b.

Marstacimab is a monoclonal antibody targeting TFPI, administered once weekly subcutaneously at a flat dose of 150 mg. In the BASIS trial, marstacimab reduced ABR by 92% vs on-demand therapy in patients without inhibitors (mean ABR 3.2 vs 38.0; rate ratio 0.08, 95% CI 0.04-0.18) ^[158]C4. In patients with inhibitors, marstacimab reduced ABR by 90% vs on-demand bypassing agents (mean ABR 5.0 vs 48.8; rate ratio 0.10, 95% CI 0.04-0.24) ^[159]C4.

Mim8 (denecimig) is a next-generation bispecific antibody with higher potency than emicizumab. In the phase 3 FRONTIER2 trial, once-weekly Mim8 reduced ABR by 97% vs on-demand treatment in patients without inhibitors (mean ABR 0.5 vs 17.9; rate ratio 0.03, 95% CI 0.01-0.07) ^[153]A1b. Monthly dosing also showed efficacy (mean ABR 1.3) ^[153]A1b.

Step 4: Gene Therapy as Definitive Treatment

Gene therapy aims to achieve sustained endogenous FVIII expression after a single administration, eliminating the need for regular prophylaxis.

Valoctocogene roxaparvovec (Roctavian) is an AAV5-based vector encoding B-domain-deleted FVIII, approved in the US and EU for adults with severe hemophilia A without pre-existing anti-AAV5 antibodies or FVIII inhibitors. In the phase 3 GENEr8-1 trial (N=134), a single infusion of 6×10¹³ vg/kg resulted in a mean ABR reduction from 4.8 (baseline on prophylaxis) to 0.8 at week 104 (mean change -4.1, 95% CI -5.4 to -2.8) ^[167]C4. At 5 years, median FVIII activity by chromogenic assay was 5.8 IU/dL (interquartile range 1.0-12.4), and 88% of participants remained free of routine prophylaxis ^[202]C4. The meta-analysis of AAV gene therapy trials (8 HA studies, 211 patients) reported an annualized decrease of 7.58 bleeding events (95% CI -11.50 to -3.67) and 117.2 fewer factor infusions (95% CI -151.86 to -82.53) ^[174]A1a.

Lentiviral gene therapy using hematopoietic stem cells (HSCs) transduced with a myeloid-directed FVIII transgene has shown proof-of-concept in a small phase 1 study (N=5), with FVIII activity levels of 5-30 IU/dL after myeloablative conditioning ^[164]C4. This approach may offer an alternative for patients ineligible for AAV due to pre-existing antibodies or liver disease.

Pre-treatment evaluation for gene therapy includes screening for anti-AAV5 antibodies, liver fibrosis (transient elastography <8 kPa), and active hepatitis ^{[152]D5[186]D5}. Post-infusion, alanine aminotransferase (ALT) must be monitored weekly for 12 weeks; ALT elevation >1.5× baseline triggers corticosteroid therapy to protect transduced hepatocytes ^{[117]C4[186]D5}.

Step 5: Monitoring and Long-term Follow-up

All patients on prophylaxis require regular assessment of bleeding events, joint health (ultrasound or MRI for subclinical hemarthropathy), inhibitor surveillance (Bethesda assay every 6-12 months or after 50 exposure days), and quality of life ^{[88]D5[169]A1c}. For patients on non-factor therapies, thromboembolic events are a rare but serious concern; concizumab was temporarily paused in explorer7 due to three nonfatal thrombotic events ^[155]A1b. The ISTH guideline recommends against routine thromboprophylaxis in patients receiving non-factor agents ^[169]A1c.

Dosing Table

Drug / Modality Comparison Table

Treatment Failure Protocol If breakthrough bleeding occurs on prophylaxis:

• For FVIII replacement: increase dose or frequency, or switch to an EHL product.
• For non-factor therapy: add on-demand FVIII or bypassing agent (rFVIIa or aPCC) for acute bleeds; consider switching to an alternative non-factor agent or FVIII prophylaxis.
• For gene therapy: if FVIII activity declines to <1 IU/dL or bleeding recurs, resume FVIII prophylaxis; consider retreatment with a different vector (not yet established).

What NOT to Do

• Do NOT use activated prothrombin complex concentrate (aPCC) at doses >100 U/kg/day in patients receiving emicizumab due to risk of thrombotic microangiopathy ^[154]A1b.
• Do NOT administer gene therapy to patients with active hepatitis, cirrhosis, or liver stiffness ≥8 kPa ^[152]D5.
• Do NOT routinely use thromboprophylaxis in patients on non-factor therapies ^[169]A1c.

Controversies and Guideline Disagreement

Pearl: For patients with severe hemophilia A, modern prophylaxis with emicizumab, efanesoctocog alfa, or other non-factor agents achieves near-zero bleeding rates, while gene therapy offers a one-time alternative that sustains FVIII activity above 5 IU/dL for at least 5 years in most recipients ^{[151]B2b[165]B2b[202]C4}.

The unique hemostatic environment in hemophilia A fundamentally reshapes three routine hematology management domains: transfusion support, perioperative and therapeutic anticoagulation, and the use of antiplatelet agents. A clinician managing a patient with hemophilia A must navigate each of these domains with a rebalanced risk calculus, where the default assumption of needing systemic thromboprophylaxis is inverted, and the threshold for intervening against thrombosis is paradoxically higher than in the general population.

Step 1: Initial Assessment and Severity Classification for Anticoagulation Decisions

Before any antithrombotic intervention, classify the patient's bleeding phenotype. The World Federation of Hemophilia guidelines stratify severity by residual FVIII activity: severe (<1 IU/dL), moderate (1-5 IU/dL), and mild (>5-40 IU/dL). For patients on prophylaxis, document the trough FVIII level and the specific agent (standard half-life vs extended half-life factor concentrates, or emicizumab). This baseline determines the risk envelope. In patients with severe hemophilia A, the endogenous thrombin generation is profoundly suppressed, the median endogenous thrombin potential (ETP) is approximately 25% of that seen in non-hemophilic patients on therapeutic vitamin K antagonists ^[238]C4 (2b). A decision to anticoagulate requires a multidisciplinary discussion involving a hemostasis specialist, a cardiologist or vascular specialist, and the patient.

Step 2: Thromboprophylaxis After Major Orthopedic Surgery, A Rebalanced Approach

Historically, pharmacologic thromboprophylaxis after total joint replacement (TJR) was considered contraindicated in hemophilia due to fear of provoking hemorrhage. However, modern factor replacement protocols restore FVIII to near-normal levels perioperatively, potentially unmasking a thrombotic risk. A systematic review including 486 TJRs in persons with hemophilia A or B reported a postoperative venous thromboembolism (VTE) rate of 2.1% (95% CI 1.0-3.7%), which is substantially lower than the 1-4% rate seen in non-hemophilic patients receiving pharmacologic prophylaxis ^[209]B2a (2a). Notably, most centers in this review did not routinely administer pharmacologic thromboprophylaxis. A separate retrospective cohort of severe hemophilia A patients undergoing simultaneous bilateral total knee arthroplasty (n=50) found a DVT incidence of only 2.0% without pharmacologic prophylaxis, using only tranexamic acid (TXA) for hemostatic support and mechanical compression devices ^[236]B2b (2b).

Recommendation: For patients with hemophilia A undergoing TJR with adequate perioperative factor replacement (target trough FVIII >50 IU/dL), mechanical thromboprophylaxis (intermittent pneumatic compression devices) is the standard. Pharmacologic prophylaxis is generally NOT indicated unless additional prothrombotic risk factors are present (prior VTE, active cancer, antiphospholipid antibodies). Do NOT use TXA concurrently with pharmacologic anticoagulation. In the rare circumstance where pharmacologic prophylaxis is deemed necessary, choose low molecular weight heparin (e.g., enoxaparin 40 mg SC daily) at a 50% dose reduction of the usual prophylactic dose, and maintain FVIII trough >30 IU/dL during the treatment period ^[211]D5 (5).

Step 3: Therapeutic Anticoagulation for Established VTE or Atrial Fibrillation

When a patient with hemophilia A develops a thrombotic event, deep vein thrombosis, pulmonary embolism, or atrial fibrillation necessitating anticoagulation, the decision pathway must weigh the competing risks of recurrent thrombosis against catastrophic bleeding. There are no randomized trials to guide therapy; evidence comes from case series and expert consensus ^[211]D5 (5).

Algorithm:

1. Establish the thrombotic indication and its acuity - Acute proximal DVT/PE requires immediate anticoagulation; chronic atrial fibrillation can be approached more deliberately.
2. Correct the FVIII deficiency - Administer factor concentrate to achieve a trough FVIII level of 30-50 IU/dL before and during the entire duration of anticoagulation. This is a higher target than the usual 1-3 IU/dL trough used for prophylaxis.
3. Choose the anticoagulant - For mild hemophilia A (baseline FVIII >5 IU/dL), direct oral anticoagulants (DOACs) are feasible, with apixaban 2.5 mg twice daily (the lower dose) or edoxaban 30 mg daily being favored due to their lower bleeding risk compared with rivaroxaban . For severe hemophilia A on emicizumab, the risk of thrombotic events with emicizumab plus activated prothrombin complex concentrates (aPCC) is well-documented ^[219]C4 (4); thus, DOACs are preferred over aPCC. For patients with inhibitors, DOACs are generally avoided due to unpredictable hemostatic impact; low molecular weight heparin with careful monitoring may be used ^[211]D5 (5).
4. Duration - For provoked VTE, 3 months of anticoagulation is sufficient; for unprovoked VTE or atrial fibrillation, an indefinite plan with periodic reassessment is appropriate, always maintaining FVIII trough >30 IU/dL.

Table 1: Anticoagulant Selection in Hemophilia A

Step 4: Antiplatelet Therapy, Cytoreduction Context

Antiplatelet agents ( aspirin , clopidogrel , prasugrel , ticagrelor ) are commonly required for secondary prevention of coronary artery disease , cerebrovascular disease, or peripheral arterial disease. In hemophilia A, these agents pose a particular risk because they impair the platelet-dependent delivery of FVIII from platelet α-granules. Preclinical studies in hemophilia A mice have demonstrated that aspirin, clopidogrel, and αIIbβ3-blocking antibodies all significantly impair hemostasis mediated by platelet-derived FVIII ^[227]D5 (5). In human patients, the combination of FVIII deficiency and antiplatelet therapy markedly increases the risk of spontaneous and trauma-related bleeding.

Recommendation: For patients with severe hemophilia A (FVIII <1 IU/dL) on prophylaxis, avoid dual antiplatelet therapy (DAPT) whenever possible. For patients requiring single antiplatelet therapy (e.g., after bare-metal stent placement), use low-dose aspirin (81 mg PO daily) with concurrent FVIII trough >5 IU/dL. If DAPT is mandatory (e.g., acute coronary syndrome with drug-eluting stent), limit duration to 1 month, then de-escalate to single agent. Clopidogrel alone is preferred over aspirin alone for long-term secondary prevention in patients with hemophilia because it has a slightly lower gastrointestinal bleeding risk ^[211]D5 (5).

Step 5: Transfusion Support, Red Cell and Platelet Strategies

Transfusion requirements in hemophilia A are driven by acute bleeding events (hemarthroses, intramuscular hematomas, gastrointestinal bleeding, intracranial hemorrhage) and/or surgical interventions. The principles differ from those in coagulopathic patients without hemophilia because factor replacement rather than fresh frozen plasma (FFP) is the foundation of hemostatic correction.

Red blood cell (RBC) transfusion: Follow restrictive thresholds (Hb <7 g/dL in hemodynamically stable patients, <8 g/dL in those with cardiovascular disease) ^[235]C4 (4). Do NOT transfuse RBCs as a "pro-hemostatic" measure; correct the underlying FVIII deficiency first. In patients undergoing simultaneous bilateral total joint arthroplasty, a high-volume blood loss scenario, the median RBC transfusion rate was 25% in one series, comparable to non-hemophilic patients ^[235]C4 (4). Tranexamic acid (TXA) 10-15 mg/kg IV at induction reduces total blood loss and transfusion requirements by approximately 30% and should be used routinely unless contraindicated (history of thrombotic event, seizure disorder) ^[236]B2b (2b).

Platelet transfusion: Not indicated for hemophilia A unless the patient has concomitant thrombocytopenia (platelet count <50 × 10⁹/L) or is on powerful antiplatelet therapy that has caused clinical bleeding. In the investigational context of platelet-targeted gene therapy, transfused FVIII-expressing platelets have been shown to restore hemostasis and induce immune tolerance in preclinical models ^[214]D5 (5). However, this remains experimental and not yet standard clinical practice.

Step 6: Monitoring and Titration, Thrombin Generation as a Surrogate

Standard coagulation assays (aPTT, PT) are inadequate for monitoring the net hemostatic effect during anticoagulation or after complex transfusion strategies. The thrombin generation assay (TGA) provides a more complete picture of the coagulation balance. The ETP measured by TGA in hemophilia A patients on therapeutic doses of DOACs or LMWH is comparable to that of non-hemophilic patients on VKAs ^[238]C4 (2b). This suggests that TGA can guide dose adjustments in real-time, particularly in scenarios where bleeding risk is amplified (e.g., concurrent antiplatelet therapy after a recent VTE). New microfluidic TGA platforms promise bedside monitoring, but are not yet widely available ^[241]D5 (5).

Practical monitoring protocol:

• Measure FVIII trough daily during acute anticoagulation (target >30 IU/dL).
• For DOACs, measure drug-specific anti-Xa levels (apixaban target peak 100-200 ng/mL; edoxaban peak 100-200 ng/mL).
• For LMWH, monitor anti-Xa 4 hours post-dose (target 1.0-2.0 IU/mL for therapeutic, 0.2-0.5 IU/mL for prophylactic).
• Perform TGA at initiation and after any dose change; target ETP between 1000-1500 nM·min (the lower end of the therapeutic range for non-hemophilic patients on VKAs) ^[238]C4 (2b).

What NOT to Do

• Do NOT administer FFP or cryoprecipitate for anticoagulation reversal in hemophilia; these do not provide sufficient FVIII for hemostasis. Use factor VIII concentrate (dosed to achieve a trough of 30-50 IU/dL) or, if unavailable, desmopressin (DDAVP 0.3 μg/kg IV, only in mild hemophilia A with known response).
• Do NOT use aPCC (FEIBA) for anticoagulation reversal in patients on emicizumab; this combination has been associated with thrombotic microangiopathy and thromboembolic events ^[219]C4 (4). If urgent reversal is required, use recombinant FVIIa (rFVIIa) 90 μg/kg IV.
• Do NOT routinely prescribe aspirin-containing products for any patient with severe hemophilia A, even as "preventive" therapy, the risk of bleeding outweighs any potential cardiovascular benefit unless compelling secondary prevention evidence exists ^[227]D5 (5).

Controversies and Guideline Disagreement

Pearl: In hemophilia A, the conventional hematology triad of transfusion, anticoagulation, and antiplatelet therapy must be inverted: mechanical thromboprophylaxis replaces pharmacologic agents routinely, and any therapeutic anticoagulation requires aggressive FVIII target correction (trough >30 IU/dL) with thrombin generation monitoring; do not use aPCC for reversal in patients on emicizumab due to prothrombotic risk ^{[209]B2a[219]C4[238]C4}.

The treatment of hemophilia A has undergone several paradigm shifts over the past century, progressing from whole-blood transfusions to recombinant factor concentrates, and now to non-factor therapies and gene therapy. Each era brought new capabilities and new complications, and the sequence of landmark trials reveals why current practice is structured as it is.

From Cryoprecipitate to Recombinant Concentrates

Before the 1960s, treatment relied on fresh frozen plasma, which provided insufficient FVIII levels to control serious bleeds. The discovery of cryoprecipitate in 1964 made it possible to raise FVIII levels with a smaller volume, transforming acute management ^[248]C4. However, plasma-derived concentrates pooled from thousands of donors, introduced in the 1970s, led to the catastrophic contamination of the hemophilia community with HIV and hepatitis C virus ^{[201]D5[266]B2b}. By the late 1980s, an estimated 80% of severe hemophilia patients were HIV-positive in some cohorts, and the 16-year incidence of AIDS was 38% ^[266]B2b. This tragedy drove the development of recombinant FVIII (rFVIII), which was first tested in previously untreated patients (PUPs) in a landmark multicenter trial published in 1993 ^[248]C4. That study demonstrated safety and efficacy in 95 patients aged <6 years, with an inhibitor incidence of 15.8% for low-titer and 10.5% for high-titer antibodies ^[248]C4. Recombinant concentrates soon became the standard of care, eliminating the risk of blood-borne virus transmission, though the debate over product type (recombinant vs. plasma-derived) and inhibitor risk would continue.

The Prophylaxis Revolution: The Joint Outcome Study

For decades, episodic (on-demand) therapy was the norm, but recurrent hemarthroses led to debilitating arthropathy by early adulthood ^[88]D5. The landmark Joint Outcome Study (JOS), published in 2007, randomized 65 boys <30 months with severe hemophilia A to prophylactic rFVIII (25 IU/kg every other day) or enhanced episodic therapy. At age 6 years, 93% of prophylaxis recipients had normal joint MRI scans compared with only 55% in the episodic group (absolute difference 38 percentage points; NNT = 3 to preserve joint integrity) ^[45]A1b. These results established prophylaxis as the standard for children, a finding later reinforced by the Joint Outcome Continuation Study, which showed durable joint health benefits through age 18 years ^[76]B2b.

Factor VIII Pharmacokinetic-Guided Dosing

The PROPEL trial, reported in 2021, asked whether targeting higher FVIII trough levels improved outcomes. It randomized 120 patients aged 12-65 years with severe hemophilia A to PK-guided prophylaxis targeting troughs of 1-3% (reference) versus 8-12% (elevated) using rurioctocog alfa pegol. The elevated-target arm had a significantly higher proportion of patients with zero bleeds (point estimate 47% vs. 32%), establishing that higher troughs reduce bleeding further ^[243]A1b. However, the intensive arm also required higher factor consumption, informing the individualization of prophylaxis targets.

Conquering Inhibitors: Bypassing Agents and Emicizumab

Inhibitor development, neutralizing alloantibodies against FVIII, was the most feared complication of hemophilia A, affecting approximately 30% of PUPs with severe disease ^{[47]B2b[44]A1b}. For decades, the only options for acute bleeding were bypassing agents: recombinant activated FVII (rFVIIa, 90 μg/kg every 2-3 hours) or activated prothrombin complex concentrate (aPCC, 85 U/kg every 8-12 hours) ^{[118]A1c[246]A1b}. A 2011 crossover trial of prophylactic aPCC (85 U/kg 3×/week) in patients with inhibitors showed a 62% reduction in bleeding episodes compared with on-demand therapy ^[246]A1b.

The pharmaceutical landscape shifted dramatically with the introduction of emicizumab, a bispecific monoclonal antibody that bridges factor IXa and factor X to mimic FVIIIa function. The HAVEN 1 trial (2017) randomized 109 patients with hemophilia A and inhibitors to emicizumab prophylaxis (3 mg/kg/week) or no prophylaxis. The annualized bleeding rate was 87% lower with emicizumab (2.9 vs. 23.3 events; P<0.001) ^[154]A1b. HAVEN 3 (2018) then demonstrated similar efficacy in patients without inhibitors, with treated ABR of 1.5 events/year versus 38.2 with no prophylaxis ^[156]A1b. Long-term pooled data across HAVEN 1-4 (median follow-up 120.4 weeks) confirmed durability: a model-based treated ABR of 1.4 events/year ^[151]B2b.

The Concizumab and Mim8 Era

Concizumab, an anti-tissue factor pathway inhibitor monoclonal antibody, represents another non-factor approach. The explorer7 trial (2023) randomized patients with hemophilia A or B with inhibitors to concizumab prophylaxis (once-daily subcutaneous) or no prophylaxis. The ABR was 75% lower with concizumab (rate ratio 0.25, 95% CI 0.10-0.63), with a zero-bleed rate of 60% in the prophylaxis arm ^[155]A1b. Longer-term results (56-week cutoff) showed sustained efficacy without new safety signals ^[162]A1b. For patients without inhibitors, explorer8 demonstrated a similar magnitude of benefit ^[204]A1b.

Mim8 (denecimig), a next-generation FVIIIa-mimetic bispecific antibody, was evaluated in the phase 3 FRONTIER trial (2026). Compared with on-demand treatment, Mim8 once weekly reduced ABR by 97% (rate ratio 0.03, 95% CI 0.01-0.09), with 85% of patients experiencing zero bleeds ^[153]A1b. Once-monthly dosing achieved a similar 95% reduction. These data position non-factor therapies as first-line prophylaxis for many patients.

Gene Therapy: From Promise to Reality

Gene therapy for hemophilia A culminated in the approval of valoctocogene roxaparvovec (AAV5-hFVIII-SQ) in Europe (2022) and the United States (2023) ^{[183]D5[163]C4}. The pivotal phase 3 study enrolled 134 men with severe hemophilia A (FVIII ≤1%). After a single intravenous infusion, the mean FVIII activity at 2 years was 14.5 IU/dL (interquartile range 8.4-23.4), and the adjusted ABR fell from 4.7 to 0.7 events/year (85% reduction) ^[163]C4. However, durability beyond 5 years and the risk of late hepatotoxicity remain under study ^{[152]D5[254]D5}. Current guidelines restrict gene therapy to adults without preexisting anti-AAV5 antibodies, uncontrolled liver infections, or cirrhosis ^[152]D5.

What Was Abandoned and Why

• Plasma-derived concentrates (except in low-resource settings): abandoned in high-income countries after 1993 due to residual viral transmission risk, despite data from SIPPET (2016) showing a lower inhibitor risk with plasma-derived vs. recombinant (25% vs. 43%; HR 0.61, 95% CI 0.38-0.98) ^{[44]A1b[201]D5}. The risk-benefit calculus shifted to prioritize viral safety.
• Desmopressin in mild disease: while still used for minor bleeds, a 2022 randomized trial showed that moderate-intensity aerobic exercise increased FVIII:C to a similar degree as intranasal desmopressin (mean rise 2.3-fold vs. 2.5-fold), providing a low-cost alternative without side effects ^[242]A1b.
• Routine prophylaxis with aPCC in inhibitor patients: largely replaced by emicizumab due to superior convenience (subcutaneous weekly vs. IV 3×/week) and bleeding reduction ^{[154]A1b[246]A1b}.

Controversies and Guideline Disagreement

Pearl: Treatment of hemophilia A has evolved from crisis-driven transfusion to prophylactic FVIII replacement, then to non-factor therapies that decouple hemostasis from the FVIII molecule, and now to gene therapy, each step driven by landmark trials that simultaneously answered pivotal questions and created new ones.

The most significant complication of hemophilia A treatment is the development of neutralizing alloantibodies (inhibitors) against factor VIII, occurring in 25-30% of patients with severe disease ^[273]D5. Inhibitors render standard factor replacement ineffective, dramatically increasing morbidity and mortality. Other major complications include intracranial hemorrhage (ICH), venous thromboembolism (VTE), transfusion-transmitted infections , hemophilic arthropathy, and treatment-related adverse events. Each complication has a defined mechanism, monitoring strategy, and prevention approach.

Inhibitor Development

Inhibitors are IgG alloantibodies that neutralize FVIII activity. Risk factors include severe F8 gene mutations (large deletions, nonsense mutations), family history, African ancestry (haplotype mismatch), and intensive treatment episodes (surgery, trauma) ^{[274]B3b[273]D5}. Nonneutralizing antibodies (NNAs) may precede inhibitor formation; in the SIPPET trial, 7.6% of previously untreated patients (PUPs) had NNAs at baseline, and their presence was associated with subsequent inhibitor development ^[43]B2b. Complement activation via C3 enhances FVIII immunogenicity, and N-glycosylation patterns of recombinant products modulate immune responses ^{[278]D5[275]B3b[276]D5}.

Monitoring: Bethesda assay for inhibitor titer (in Bethesda units, BU) after every 5-10 exposure days or annually in stable patients. A titer ≥0.6 BU is considered positive; high-titer inhibitors (>5 BU) predict poor response to FVIII replacement ^[143]D5.

Prevention: Use of emicizumab prophylaxis in PUPs reduces FVIII exposure and may lower inhibitor risk, though definitive data are pending. Avoiding intensive FVIII treatment during inflammatory states (infection, surgery) is recommended when possible ^[26]D5.

Management : Immune tolerance induction (ITI) with daily high-dose FVIII eradicates inhibitors in 60-80% of patients ^[181]D5. For bleeding, bypassing agents (recombinant factor VIIa 90 μg/kg every 2-3 hours or activated prothrombin complex concentrate 50-100 U/kg every 6-12 hours) are first-line ^[143]D5. Emicizumab, a bispecific antibody mimicking FVIIIa, is approved for prophylaxis in patients with inhibitors and reduces annualized bleeding rate by 87% compared to no prophylaxis ^[181]D5.

Intracranial Hemorrhage

ICH is a life-threatening complication with a pooled incidence of 0.5-2% per year in congenital hemophilia A and a mortality rate of 20-30% ^[48]A1a. Neonates are at highest risk, especially after traumatic delivery. Prevention relies on factor prophylaxis maintaining trough levels >1% and prompt treatment of head trauma. Management requires immediate factor replacement to achieve 100% activity, neurosurgical evacuation if indicated, and intensive care monitoring ^[48]A1a.

Venous Thromboembolism

VTE risk is low in untreated hemophilia but increases with factor replacement, bypassing agents, and emicizumab (especially when combined with activated prothrombin complex concentrate). After major orthopedic surgery, the VTE rate is 0.5-2% with appropriate factor coverage, compared to 40-60% in non-hemophilic patients ^[209]B2a. Pharmacologic thromboprophylaxis (e.g., enoxaparin 40 mg subcutaneously once daily) is considered only when factor levels are maintained >50% and bleeding risk is low; mechanical prophylaxis is preferred ^[209]B2a.

Hepatitis C and Liver Disease

Before viral inactivation of plasma-derived products, 80-90% of multitransfused patients acquired hepatitis C virus (HCV) ^[210]B2b. Chronic HCV leads to cirrhosis and hepatocellular carcinoma, and liver health is critical before gene therapy ^[186]D5. Prevention now relies on recombinant products and universal screening. Management includes direct-acting antivirals with cure rates >95% ^[210]B2b.

Hemophilic Arthropathy

Recurrent joint bleeds cause synovitis, cartilage damage, and end-stage arthropathy. Without prophylaxis, >90% of severe patients develop arthropathy by adulthood ^[280]B2a. Prevention is primary prophylaxis starting before age 2. Management includes physiotherapy, synovectomy, and total joint arthroplasty (TJA). TJA in hemophilia has a 10-year prosthesis survival of 85-90%, but complication rates are higher: infection 5-10%, aseptic loosening 10-15%, and bleeding 10-20% ^[280]B2a.

Acquired Hemophilia A (as a Treatment Complication)

Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies to FVIII, but it can occur as an immune-related adverse event of immune checkpoint inhibitors (ICIs) ^[38]C4. Among ICI-treated patients, AHA incidence is <0.1% but carries high bleeding mortality. Management includes holding ICI, using emicizumab for hemostasis (6 mg/kg day 1, 3 mg/kg day 2, then 1.5 mg/kg weekly), and immunosuppression with corticosteroids ± rituximab ^{[20]D5[176]C4[281]B2a}.

Gene Therapy-Related Complications

Adeno-associated virus (AAV) gene therapy can cause liver inflammation (elevated transaminases in 30-50% of patients) due to T-cell responses against transduced hepatocytes ^[186]D5. Prevention requires pre-treatment liver assessment (HCV, steatosis) and monitoring of FVIII levels and liver enzymes. Management includes corticosteroids (e.g., prednisolone 60 mg daily with taper) to suppress immune response and preserve FVIII expression ^[186]D5.

Supportive Care in Hospitalized Patients

Respiratory Monitoring

Airway bleeding (neck, chest) or massive hemoptysis requires close monitoring of respiratory status. Forced vital capacity (FVC) thresholds: <20 mL/kg indicates need for noninvasive ventilation; <15 mL/kg may require intubation. Intubation criteria include inability to protect airway, hypoxia (PaO2 <60 mmHg), or hypercapnia (PaCO2 >50 mmHg).

Autonomic Complications

CNS bleeding or severe pain can cause autonomic instability: arrhythmias ( atrial fibrillation , bradycardia), blood pressure lability, ileus, and urinary retention. Management includes continuous telemetry, fluid resuscitation, and symptomatic treatment (e.g., metoclopramide 10 mg IV for ileus, intermittent catheterization for retention).

DVT/PE Prophylaxis

In hemophilia patients hospitalized for surgery or acute illness, pharmacologic thromboprophylaxis is controversial. When factor levels are maintained >50% with replacement, low molecular weight heparin (enoxaparin 40 mg subcutaneously once daily) or unfractionated heparin (5000 U subcutaneously twice daily) can be used with close monitoring for bleeding ^[209]B2a. Mechanical prophylaxis (intermittent pneumatic compression) is safer and should be used in all patients.

Pain Management

Acute pain from joint bleeds: acetaminophen 500-1000 mg every 6 hours (max 4 g/day) is first-line. NSAIDs (ibuprofen 400-600 mg every 6 hours) are avoided due to antiplatelet effect and bleeding risk; COX-2 inhibitors (celecoxib 200 mg daily) may be used cautiously. Severe pain requires opioids: morphine 5-10 mg IV every 2-4 hours or hydromorphone 1-2 mg IV every 3-4 hours. Chronic arthropathy pain benefits from gabapentin 300-600 mg three times daily or amitriptyline 25-50 mg at bedtime.

Rehabilitation

Rehabilitation begins immediately after joint bleed resolution (typically 48-72 hours after factor replacement). Modalities include range-of-motion exercises, isometric strengthening, and proprioceptive training. For chronic arthropathy, physical therapy focuses on maintaining joint function and preventing contractures. After TJA, early mobilization with factor coverage is essential.

Hospital-Acquired Complications

• Pneumonia: Prevention with incentive spirometry, early mobilization. Management: empiric antibiotics per local guidelines.
• Pressure injury: Prevention with turning every 2 hours, pressure-relieving mattresses. Management: wound care, offloading.
• Urinary tract infection: Prevention with avoiding unnecessary catheters, early removal. Management: culture-directed antibiotics.

Complication Table

Controversies and Guideline Disagreement

Pearl: Inhibitor development remains the most consequential complication of hemophilia A treatment, occurring in one-quarter of severe patients; early detection via Bethesda monitoring and prompt use of bypassing agents or emicizumab are critical to reduce morbidity and mortality ^{[273]D5[181]D5}.

The trajectory of hemophilia A is fundamentally determined by the severity of the factor VIII deficiency, the presence of an inhibitor, and the treatment epoch in which the patient received care. In the pre-prophylaxis era, the outlook for severe hemophilia A was one of progressive, debilitating joint disease and premature death. Modern therapy has transformed this prognosis into one of near-normal life expectancy for most patients, though significant morbidity and mortality persist in specific subgroups.

Survival and Mortality

Persons with hemophilia A continue to have a modestly elevated all-cause mortality rate compared with the general male population, though the gap is narrowing. A systematic literature review of 18 studies (2010-2020) reported a standardised mortality ratio (SMR) that ranged from 1.3 to 2.7 for severe hemophilia, with the highest SMRs in patients with inhibitors and those co-infected with HIV or hepatitis C ^[271]A1a. The leading causes of death in the modern era are intracranial hemorrhage (ICH), malignancy, and liver disease from transfusion-transmitted hepatitis. ICH remains a leading cause of death across all age groups; the pooled incidence of ICH in patients with hemophilia of all severities is 1.6 per 1000 person-years, with a case-fatality rate of 18.1% ^[48]A1a. In neonates, the incidence of ICH is substantially higher, 3.4 per 1000 live births among those with severe hemophilia, and mortality in this group approaches 20% ^[48]A1a. Chronic hepatitis C, a legacy of plasma-derived concentrate use before the 1990s, accounts for a significant proportion of late deaths due to cirrhosis and hepatocellular carcinoma ^[210]B2b.

Joint Outcomes: The Primary Morbidity

The natural history of severe hemophilia A (baseline FVIII < 1 IU/dL) without prophylaxis is one of recurrent spontaneous hemarthroses beginning in early childhood. The landmark Joint Outcome Study (JOS) demonstrated that by age 6 years, only 45% of boys treated with an enhanced episodic (on-demand) regimen, compared with 93% of those on primary prophylaxis, had normal joint magnetic resonance imaging (MRI) of index joints (ankles, knees, elbows) ^[45]A1b. The Joint Outcome Continuation Study (JOS-C) followed 37 of these patients through age 18 years and found that early prophylaxis (starting before age 30 months) conferred a durable structural benefit: mean osteochondral MRI scores were significantly lower in the early-prophylaxis group (3.3 vs 10.8, p = 0.049), and this group had fewer joint bleeds annually ^[76]B2b. These data confirm that primary prophylaxis initiated before age 2.5 years is the single most important intervention to preserve joint health into young adulthood.

Bleeding Phenotype and Intracranial Hemorrhage

A clinically useful bleeding-risk stratification tool is the PREDICT risk score, which assigns patients a low, medium, or high risk of bleeding based on five phenotypic and biologic variables: baseline FVIII level, annualized bleeding rate before prophylaxis, presence of target joints, joint range-of-motion deficits, and time to first hemarthrosis ^[267]B2b. In a prospective cohort, patients classified as high-risk had a 4.2-fold higher annual bleeding rate while on standard-half-life prophylaxis than low-risk patients ^[267]B2b.

ICH requires particular emphasis. The incidence peaks in the neonatal period and again in older adults. In the meta-analysis by Zwagemaker et al., the pooled ICH incidence in patients of all ages was 1.6 per 1000 person-years (95% CI, 1.1-2.3), with a mortality rate of 18.1% (95% CI, 10.6-29.2) ^[48]A1a. Inhibitor presence dramatically amplifies ICH risk, with a relative risk of approximately 3 compared with non-inhibitor patients ^[48]A1a.

Inhibitors as a Prognostic Turning Point

Inhibitor development remains the most consequential complication of hemophilia A care, and it independently worsens prognosis. The cumulative incidence of all inhibitors in previously untreated children with severe hemophilia A is 32.4% (95% CI, 28.6-36.5), with high-titer inhibitors (≥5 BU) occurring in 20.2% (95% CI, 17.0-23.9) ^[60]B2b. The SIPPET trial confirmed that the risk of inhibitor development is product-dependent: recombinant FVIII products conferred a 1.87-fold higher risk of high-titer inhibitor development than plasma-derived FVIII products containing von Willebrand factor (VWF) ^[60]B2b. The F8 genotype is the strongest determinant of inhibitor risk; large deletions and nonsense mutations carry odds ratios for inhibitor development of 7.19 (95% CI, 3.05-16.89) and 4.65 (95% CI, 2.23-9.70), respectively, compared with intron 22 inversions ^[13]B2a.

In persons with nonsevere hemophilia A (baseline FVIII 5-40 IU/dL), inhibitors are less common (2.6% prevalence) but when they occur, they dramatically alter the prognosis. A US registry study of 6624 persons with nonsevere HA found that those with inhibitors had a mortality rate of 7.7 per 1000 person-years compared with 2.4 per 1000 person-years in those without, a statistically significant 2.9-fold increase ^[288]B2b. Causes of death in this inhibitor-positive subgroup were primarily hemorrhage and infection.

Acquired Hemophilia A: An Exceptionally High-Mortality Subgroup

Acquired hemophilia A (AHA) carries a distinctly worse prognosis than congenital disease, with reported overall mortality rates of 10-30% within the first year, driven largely by complications of immunosuppressive therapy (IST) rather than bleeding itself ^{[118]A1c[179]D5}. The landmark GTH-AH 01/2010 study showed that the presence of anti-FVIII IgA autoantibodies at baseline predicts poor outcome: IgA-positive patients had a significantly lower rate of partial remission (hazard ratio, 0.41; p < 0.05) ^[131]B2b. The GTH-AHA-EMI study recently demonstrated that a strategy of bleeding prophylaxis with emicizumab while deferring IST for 12 weeks was associated with a 56% relative reduction in mortality compared with a propensity-score-matched cohort receiving immediate IST (HR 0.44, p = 0.05), driven by fewer infection-related deaths ^[170]B2b. These findings underscore that in AHA, the prognosis is determined more by the intensity and complications of IST than by the bleeding phenotype.

Gene Therapy: A New Prognostic Horizon

For patients with severe hemophilia A without inhibitors, adeno-associated virus (AAV) vector gene therapy (valoctocogene roxaparvovec) has emerged as a disease-modifying therapy. Pivotal trials have demonstrated that a single infusion can achieve sustained factor VIII expression in most recipients, eliminating the need for routine prophylaxis and dramatically reducing annualized bleeding rates to near zero ^[286]D5. However, long-term durability and risks remain under study: AAV DNA integration into the host genome is a theoretical concern for late malignant transformation ^[254]D5, and a proportion of patients lose sufficient FVIII expression over time to require resumption of prophylaxis ^[286]D5. The prognostic impact of gene therapy on mortality and long-term joint health will require follow-up beyond the current 5- to 10-year trial windows.

Summary Curve

Pearl: The prognosis of severe hemophilia A has been revolutionized by primary prophylaxis and inhibitor management ; life expectancy now approaches the general population, but uncontrolled inhibitor patients and acquired hemophilia A patients still face a 10-30% one-year mortality driven largely by ICH and treatment-related infections, respectively ^{[48]A1a[271]A1a[170]B2b}.

Management of hemophilia A must be adapted across the lifespan and in special clinical contexts, with modifications to diagnosis, treatment intensity, and monitoring. These populations - from neonates to the elderly, and during pregnancy - present distinct challenges that are not fully addressed by standard protocols.

Pediatrics

Infants and toddlers with severe hemophilia A have a unique bleeding profile. Intracranial hemorrhage (ICH) occurs in 7.7% of children under two years, with 75% of cases before age 1 year ^[111]B2b. Prophylaxis initiation within the first year of life is now standard; the mean age at start in US centers is 10.3 months, with earlier initiation in later birth cohorts ^[111]B2b. The risk of ICH declines substantially once prophylaxis is established.

For previously untreated patients (PUPs), inhibitor development remains the central challenge. In the PUPs A-LONG trial of recombinant factor VIII Fc fusion protein (rFVIIIFc), inhibitor incidence was 31.1% (95% CI 21.8-41.5%), with 18.4% high-titer (>5 BU) ^[47]B2b. Similarly, the pathfinder6 trial of turoctocog alfa pegol (N8-GP) reported a 29.9% overall inhibitor rate (14.9% high-titer) ^[50]B2b. High-risk F8 mutations (e.g., intron 22 inversions, nonsense mutations) are present in 80% of PUPs who develop inhibitors ^[47]B2b. A family history of inhibitors also increases risk ^[302]B2b.

Extended half-life products offer the advantage of less frequent dosing in children. Once-weekly efanesoctocog alfa (50 IU/kg) provided high sustained FVIII levels (mean trough >40 IU/dL) in children <12 years, with a median annualized bleed rate (ABR) of 0.0 (IQR 0.0-1.0) ^[166]C4. A post-hoc analysis of XTEND-Kids confirmed that >95% of bleeding episodes were controlled with 1-2 doses ^[295]B2b.

Dose modifications: Pediatric pharmacokinetics differ from adults due to higher clearance and lower von Willebrand factor (VWF) levels. Population PK models incorporating age, weight, and VWF:Ag are essential for dose individualization in children ^{[137]D5[293]B2b}. Concomitant thrombophilic mutations (factor V Leiden, prothrombin G20210A) are associated with a significantly lower annual bleeding frequency and reduced joint damage, an effect that may be considered when planning prophylaxis intensity ^[299]B2b.

Pregnancy and Hemophilia Carriers

Hemophilia carriers (HCs) face increased bleeding risk during pregnancy and delivery, even with normal baseline FVIII levels. A systematic review of qualitative studies found that HCs experience significant psychosocial challenges regarding reproductive decision-making, prenatal diagnosis, and childbirth, often feeling insufficiently supported by healthcare providers ^[100]D5.

Preconception and prenatal care: Genetic counseling and carrier testing are essential. Over two decades of global data show that 78.3% of 969 pregnancies in hemophilia families underwent prenatal diagnosis, with amniocentesis (45.8%) and chorionic villus sampling (36.4%) being the most common methods ^[126]B2a. Preimplantation genetic testing is an option for families with known mutations.

During pregnancy: FVIII levels rise physiologically, peaking in the third trimester, but this increase is variable. FVIII levels should be checked at 28 and 34 weeks to guide delivery planning ^[296]D5. Women with baseline FVIII <50 IU/dL or a history of bleeding should receive tranexamic acid 1 g orally every 6 hours during labor and for 7-10 days postpartum ^[296]D5. Desmopressin (DDAVP) can be used in carriers who have previously demonstrated a response, but is contraindicated in preeclampsia and should be used with caution due to the risk of hyponatremia ^[283]A1a.

Delivery planning: A multidisciplinary team - hematologist, obstetrician, anesthesiologist, and pediatric hematologist - is required. Neuraxial anesthesia is safe if FVIII levels are >50 IU/dL at the time of placement ^[296]D5. If FVIII is <50 IU/dL, FVIII concentrate (or DDAVP if responsive) should be administered to raise levels. Cesarean section is recommended only for obstetric indications, not solely due to carrier status.

Postpartum hemorrhage (PPH): Despite adherence to guidelines, PPH remains a risk. FVIII levels drop rapidly after delivery, often to pre-pregnancy levels within 24-48 hours. Tranexamic acid and, if needed, FVIII concentrate should be available. Breastfeeding is safe; FVIII is not secreted into breast milk in significant amounts ^[296]D5.

Elderly

The aging hemophilia population presents a growing challenge. Comorbidities - particularly cardiovascular disease (CVD), renal impairment, and arthritis - complicate management ^[294]A1c. Antithrombotic therapy for atrial fibrillation or venous thromboembolism requires careful shared decision-making. The EHA-ISTH-EAHAD-ESO guidance recommends that in hemophilia A patients with CVD, anticoagulation is not contraindicated if FVIII levels are maintained, but a modified thromboprophylaxis regimen (e.g., direct oral anticoagulants at reduced doses) may be appropriate ^[294]A1c. The risk of VTE after major orthopedic surgery is low (systematic review rate 0.5-1.5%), and routine pharmacologic thromboprophylaxis is not recommended unless additional risk factors are present ^[209]B2a.

Renal/hepatic impairment: Dose adjustment for FVIII concentrates is not generally required, as the liver is not involved in clearance of FVIII itself. However, patients with cirrhosis have impaired synthesis of coagulation factors and reduced VWF levels, affecting FVIII pharmacokinetics. In renal impairment, desmopressin is contraindicated (risk of water retention, hyponatremia). Emicizumab requires no dose adjustment for mild-to-moderate renal impairment, but caution is advised in severe renal disease due to limited data [label].

Immunocompromised Patients

Patients with hemophilia A who are immunocompromised - due to HIV (common historically), immunosuppressive therapy, or after organ transplantation - have no specific dose adjustments for FVIII concentrates. However, the response to immune tolerance induction (ITI) may be altered. Nonneutralizing antibodies (NNAs) against FVIII have been detected in 7.6% of previously untreated patients at baseline and may be associated with later inhibitor development ^[43]B2b. In immunocompromised hosts, the incidence of inhibitors may be lower, but data are sparse.

Gene therapy considerations: Liver health is critical for successful adeno-associated virus (AAV) vector-mediated gene therapy. Patients with current or past chronic hepatitis C, metabolic dysfunction-associated steatohepatitis (MASH), or other liver conditions require thorough evaluation before gene therapy ^[186]D5. Immunosuppression for gene therapy may increase infection risk in already immunocompromised patients.

Pearl: In pediatric hemophilia A, the risk of intracranial hemorrhage is highest before age 1 year, making early prophylaxis initiation critical; for hemophilia carriers, multidisciplinary planning with FVIII monitoring during pregnancy and tranexamic acid prophylaxis postpartum is essential to reduce peripartum bleeding ^{[111]B2b[296]D5}.